390 related articles for article (PubMed ID: 26694174)
1. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.
Yang MC; Lin RW; Huang SB; Huang SY; Chen WJ; Wang S; Hong YR; Wang C
Cell Cycle; 2016; 15(3):394-402. PubMed ID: 26694174
[TBL] [Abstract][Full Text] [Related]
2. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells.
Wang C; Huang SB; Yang MC; Lin YT; Chu IH; Shen YN; Chiu YH; Hung SH; Kang L; Hong YR; Chen CH
PLoS One; 2015; 10(3):e0120913. PubMed ID: 25811469
[TBL] [Abstract][Full Text] [Related]
3. P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage.
Lin RW; Ho CJ; Chen HW; Pao YH; Chen LE; Yang MC; Huang SB; Wang S; Chen CH; Wang C
Cell Cycle; 2018; 17(17):2175-2186. PubMed ID: 30198376
[TBL] [Abstract][Full Text] [Related]
4. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
6. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
7. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate.
Hastak K; Agarwal MK; Mukhtar H; Agarwal ML
FASEB J; 2005 May; 19(7):789-91. PubMed ID: 15764647
[TBL] [Abstract][Full Text] [Related]
8. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
[TBL] [Abstract][Full Text] [Related]
10. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
[TBL] [Abstract][Full Text] [Related]
11. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin.
Lim DY; Park JH
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1060-8. PubMed ID: 19264955
[TBL] [Abstract][Full Text] [Related]
12. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
[TBL] [Abstract][Full Text] [Related]
13. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
14. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis.
Follis AV; Chipuk JE; Fisher JC; Yun MK; Grace CR; Nourse A; Baran K; Ou L; Min L; White SW; Green DR; Kriwacki RW
Nat Chem Biol; 2013 Mar; 9(3):163-8. PubMed ID: 23340338
[TBL] [Abstract][Full Text] [Related]
15. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
16. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
Tang DG; Li L; Chopra DP; Porter AT
Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
[TBL] [Abstract][Full Text] [Related]
18. Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family.
Ohno I; Eibl G; Odinokova I; Edderkaoui M; Damoiseaux RD; Yazbec M; Abrol R; Goddard WA; Yokosuka O; Pandol SJ; Gukovskaya AS
Am J Physiol Gastrointest Liver Physiol; 2010 Jan; 298(1):G63-73. PubMed ID: 19762431
[TBL] [Abstract][Full Text] [Related]
19. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.
Tagscherer KE; Fassl A; Sinkovic T; Combs SE; Roth W
Apoptosis; 2012 Feb; 17(2):187-99. PubMed ID: 22002102
[TBL] [Abstract][Full Text] [Related]
20. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]